All the following are manifestations of CMV infection following Lung transplant Except

CMV is a common and dangerous DNA virus in transplant recipients. It does not generally appear until the end of the first posttransplant month. Patients at highest risk for severe CMV disease are those without anti-CMV antibodies who receive a graft from a CMV antibody-positive donor (15% moality).Early diagnosis in a febrile patient with clinical suspicion of CMV disease can be made by determining CMV viral load in the blood. A rise in IgM antibodies to CMV is also diagnostic. Tissue invasion of CMV is common in the gastrointestinal tract and lungs. CMV retinopathy occurs late in the course, if untreated. Valganciclovir is a cost-effective and bioavailable oral form of ganciclovir that has been proved effective in both prophylaxis and treatment of CMV disease.Reference: Harrison; 19th edition; Page no: 1831